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Abstract
An ever-growing body of research suggests that inflammation is one of the primary causes
of diabetic retinopathy, as the inflammation can lead to insulin resistance. Beta-adrenergic re-
ceptor agonists can reduce the inflammation in human retinal endothelial cells (HRECs), but are
not a viable treatment due to systemic effects. Epac1 lies downstream of beta-adrenergic receptor
signaling, and it may have the capability to reduce inflammation by acting as an alternative path-
way for beta-adrenergic receptor agonists to block inflammatory cytokines such as tumor necrosis
factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1B). We hypothesized that the Epac1 agonist
will decrease cytokine levels, leading to improved insulin signal transduction in the retina.
HRECs were grown in normal (5mM) or high glucose (25mM). Some cells were not treated with
the Epac1 agonist and serve as controls. Western blotting was done using primary antibodies for
total and phosphorylated insulin receptor substrate-1 (IRS-1), insulin receptor (IR) and Akt, as well
as beta actin as a control for loading. Anti-Rabbit IgG/HRP was used for secondary antibodies.
ELISA analyses were done for protein levels of TNF-alpha and IL-1B. We are not done with data
analyses, but we expect to find that Epac1 will increase insulin receptor and Akt phosphorylation,
while reducing TNF-alpha and IL-1B levels.
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ABSTRACT   
An ever-growing body of research suggests that inflammation is one of the primary causes 
of diabetic retinopathy, as the inflammation can lead to insulin resistance. Beta-adrenergic receptor 
agonists can reduce the inflammation in human retinal endothelial cells (HRECs), but are not a 
viable treatment due to systemic effects. Epac1 lies downstream of beta-adrenergic receptor 
signaling, and it may have the capability to reduce inflammation by acting as an alternative 
pathway for beta-adrenergic receptor agonists to block inflammatory cytokines such as tumor 
necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1B). We hypothesized that the Epac1 
agonist will decrease cytokine levels, leading to improved insulin signal transduction in the retina.  
HRECs  were grown in normal (5mM) or high glucose (25mM).  Some cells were not 
treated with the Epac1 agonist and serve as controls. Western blotting was done using primary 
antibodies for total and phosphorylated insulin receptor substrate-1 (IRS-1), insulin receptor (IR) 
and Akt, as well as beta actin as a control for loading.  Anti-Rabbit IgG/HRP was used for 
secondary antibodies. ELISA analyses were done for protein levels of TNF-alpha and IL-1B.  We 
are not done with data analyses, but we expect to find that Epac1 will increase insulin receptor and 
Akt phosphorylation, while reducing TNF-alpha and IL-1B levels. 
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